{"title":"Integration of novel biomarkers in prospective trials: biological insights from CHOICE-01","authors":"Edward Christopher Dee, Puneeth Iyengar","doi":"10.1038/s41392-024-02078-7","DOIUrl":null,"url":null,"abstract":"<p>The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in <i>Signal Transduction and Targeted Therapy</i>,<sup>1</sup> recapitulated findings from an earlier publication of the trial.<sup>2</sup> The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable <i>EGFR</i> or <i>ALK</i> mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"16 1","pages":""},"PeriodicalIF":40.8000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Signal Transduction and Targeted Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41392-024-02078-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in Signal Transduction and Targeted Therapy,1 recapitulated findings from an earlier publication of the trial.2 The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable EGFR or ALK mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.
最近发表在《信号转导和靶向治疗》（Signal Transduction and Targeted Therapy）杂志上的CHOICE-01研究报告了总生存期（OS），总结了该试验早期发表的研究结果选择-01研究人员前瞻性地将没有靶向EGFR或ALK突变的局部晚期（IIIB或IIIC）或转移性非小细胞肺癌（NSCLC）患者随机分配到有或没有托利帕单抗（一种人源化PD-1定向IgG4抗体）的化疗中，并证明托利帕单抗可改善OS。
期刊介绍：
Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy.
Scope: The journal covers research on major human diseases, including, but not limited to:
Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
